Clearside Biomedical (CLSD) has issued an announcement.
Clearside Biomedical, Inc. has appointed Anthony S. Gibney, a seasoned executive with a rich history in biotech and investment banking, as a new Class III director, with his term expiring at the 2025 annual stockholders’ meeting. Gibney’s impressive resume includes leadership roles at IVERIC bio, Fog Pharmaceuticals, and Achillion Pharmaceuticals, as well as board positions at LAPIX Therapeutics and InflaRx N.V. In his new role, he will receive a stock option grant and an annual retainer, aligning with the company’s compensation policy for non-employee directors.
For a thorough assessment of CLSD stock, go to TipRanks’ Stock Analysis page.
